Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:01:20 2024-07-16 EDT			After market 19:00:10
29.5 ^USD	+1.37%		29.5	0.00%

10:20am	EU court criticizes Commission over handling of COVID vaccine contracts	RE
07-15	Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	CI

PFIZER INC : From a Buy to Neutral rating by UBS

January 26, 2023 at 08:24 am

UBS downgrades his rating from Buy to Neutral. Previously set at USD 55, the target price is lowered to USD 47.

Latest news about Pfizer, Inc.

EU court criticizes Commission over handling of COVID vaccine contracts	04:20am	RE
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis	07-15	CI
Health Care Up as Momentum Builds -- Health Care Roundup	07-12	DJ
UBS Raises Price Target on Pfizer to $30 From $28, Maintains Neutral Rating	07-12	MT
PFIZER INC : Receives a Buy rating from Goldman Sachs	07-12	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	07-11	MT
PFIZER INC : Jefferies keeps its Buy rating	07-11	ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading	07-11	MT
Top Midday Stories: Bain Capital to Acquire Envestnet; Delta, Pepsi Report Q2 Earnings; Pfizer Advances Development of Weight-Loss Pill; DOE Pledges $1.7 Billion for EV	07-11	MT
Sector Update: Health Care Stocks Advance Premarket Thursday	07-11	MT
Sector Update: Health Care	07-11	MT
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech	07-11	MT
Pfizer: advances in anti-obesity pill danuglipron	07-11	CF
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech	07-11	MT
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Ahead of Key Inflation Data	07-11	MT
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron	07-11	MT
Futures edge lower ahead of inflation test; Delta Airlines falls	07-11	RE
Pfizer Picks Once-Daily Obesity Pill Version for Further Study	07-11	DJ
Pfizer moves forward with once-daily weight loss drug	07-11	RE
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron	07-11	CI
Pfizer: collaboration agreement with Evotec in France	07-10	CF
Barclays Adjusts Pfizer's Price Target to $30 From $28	07-10	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	07-10	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	07-10	MT

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.5 USD

Average target price

32.1 USD

Spread / Average Target

+8.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	+2.47%	167B
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+33.88%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+12.19%	234B
NOVARTIS AG	+16.14%	225B
AMGEN INC.	+15.67%	179B
SANOFI	+2.31%	125B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : From a Buy to Neutral rating by UBS

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals